Oral contraceptives and neoplasia.
D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced / Q000473:pathology; D002822:Choriocarcinoma / Q000139:chemically induced; D002908:Chronic Disease; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003279:Contraceptives, Oral, Sequential / Q000009:adverse effects; D004714:Endometrial Hyperplasia / Q000139:chemically induced; D004964:Estriol / Q000378:metabolism; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced; D008297:Male; D008413:Mastitis / Q000139:chemically induced; D008875:Middle Aged; D009214:Myoma / Q000139:chemically induced; D009369:Neoplasms / Q000139:chemically induced*; D010051:Ovarian Neoplasms / Q000139:chemically induced; D010911:Pituitary Neoplasms / Q000139:chemically induced; D011247:Pregnancy; D011374:Progesterone / Q000009:adverse effects; D011446:Prospective Studies; D012189:Retrospective Studies; D012306:Risk; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000139:chemically induced
D003276:Contraceptives, Oral; D003279:Contraceptives, Oral, Sequential; D004967:Estrogens; D011374:Progesterone; D004964:Estriol